We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
-0.93%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.68B
AUM Growth
-$472M
Cap. Flow
-$289M
Cap. Flow %
-10.8%
Top 10 Hldgs %
51.96%
Holding
86
New
15
Increased
18
Reduced
20
Closed
23

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$97.1M
2
DVAX
Dynavax Technologies
DVAX
+$63.7M
3
GPCR icon
Structure Therapeutics
GPCR
+$56M
4
HRMY icon
Harmony Biosciences
HRMY
+$49.8M
5
IMVT icon
Immunovant
IMVT
+$46.9M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$198M
2
NTLA icon
Intellia Therapeutics
NTLA
+$102M
3
ALKS icon
Alkermes
ALKS
+$98M
4
VRNA
Verona Pharma
VRNA
+$87.5M
5
AXSM icon
Axsome Therapeutics
AXSM
+$77M

Sector Composition

Rank Sector Weight
1 Healthcare 99.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PYXS icon
76
Pyxis Oncology
PYXS
$168M
– –
-4,184,100
Closed -$15.4M
RLMD icon
77
Relmada Therapeutics
RLMD
$557M
– –
-674,833
Closed -$2.19M
RNAM
78
DELISTED
Avidity Biosciences
RNAM
– –
-475,000
Closed -$21.8M
SLN
79
Silence Therapeutics
SLN
$495M
– –
-1,000,000
Closed -$18.2M
SRRK icon
80
Scholar Rock
SRRK
$5.67B
– –
-48,100
Closed -$385K
TGTX icon
81
TG Therapeutics
TGTX
$7.96B
– –
-1,725,000
Closed -$40.3M
TVTX icon
82
Travere Therapeutics
TVTX
$5.2B
– –
-531,857
Closed -$7.44M
VIGL
83
DELISTED
Vigil Neuroscience
VIGL
– –
-1,553,996
Closed -$5.28M
ANRO icon
84
Alto Neuroscience
ANRO
$1.05B
– –
-219,648
Closed -$2.51M
MGX icon
85
Metagenomi Therapeutics
MGX
$44.8M
– –
-307,500
Closed -$667K
SYRS
86
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-828,485
Closed -$1.78M
1 2 3
4

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Deep Track Capital held 86 positions worth $2.68B, down 15% from $3.15B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Deep Track Capital withdrew a net $289M in Q4 2024, closing 23 positions and reducing 20 holdings. Its most notable exit was argenx, an estimated $198M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier.

Against the trend, Deep Track Capital opened a new position in Harmony Biosciences worth $49.9M.

  • Deep Track Capital's largest Q4 2024 buy was Harmony Biosciences: 1,450,000 shares worth $49.9M.
  • Deep Track Capital added most to Cytokinetics in Q4 2024, an estimated $97.1M increase.
  • Deep Track Capital's biggest Q4 2024 reduction was Verona Pharma, cutting an estimated $87.5M.
  • Deep Track Capital fully exited argenx in Q4 2024, selling an estimated $198M.
  • Deep Track Capital's ten largest holdings make up 52% of its $2.68B portfolio in Q4 2024.
  • Deep Track Capital opened 15 new positions and closed 23 in Q4 2024.
  • Deep Track Capital's portfolio value fell 15% quarter-over-quarter to $2.68B.

Based on Deep Track Capital's 13F filing for Q4 2024, filed 14 Feb 2025.